c-RET
c-RET inhibitors target the RET (Rearranged during Transfection) proto-oncogene, which encodes a receptor tyrosine kinase involved in cell growth, differentiation, and survival. Abnormal activation of RET signaling can lead to uncontrolled cell proliferation and resistance to apoptosis, contributing to the development of cancers such as medullary thyroid carcinoma and non-small cell lung cancer. Inhibiting c-RET can induce apoptosis in cancer cells and is a promising approach in targeted cancer therapy. At CymitQuimica, we offer a variety of high-quality c-RET inhibitors to support your research in oncology, signal transduction, and apoptosis.
Found 61 products of "c-RET"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
RET-IN-17
CAS:RET-IN-17 inhibits RET kinase; may help in IBS pain and RET-activated cancers.Formula:C27H28F4N4O4Color and Shape:SolidMolecular weight:548.53RET-IN-9
CAS:RET-IN-9 is a potent RET kinase inhibitor, potentially useful for studying RET-related diseases, including lung and thyroid cancer.Formula:C26H27N9OColor and Shape:SolidMolecular weight:481.55LRRK2-IN-17
CAS:LRRK2-IN-17 is an orally active LRRK2 inhibitor with IC50 values of 3.5 nM for WT and 3.3 nM for G2019S, and it also inhibits RET kinase with an IC50 of 59 nM. LRRK2-IN-17 is utilized in research related to cancer and Parkinson's disease (PD).Formula:C18H18N8Color and Shape:SolidMolecular weight:346.39FHND5071 (1H)
CAS:FHND5071 (1H) is a selective inhibitor of RET (rearranged during transfection) tyrosine kinase. It shows potential for research applications in RET-driven cancers, such as thyroid and lung cancer.Formula:C30H33N9OColor and Shape:SolidMolecular weight:535.64TAS05567
CAS:TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).Formula:C21H29N9O2Purity:98%Color and Shape:SolidMolecular weight:439.51RET-IN-30
CAS:RET-IN-30 (Compound 28) is a RET inhibitor that exhibits inhibitory activity against both wild-type RET and some of its mutants. It is capable of inhibiting the proliferation of A549 cells and demonstrates antitumor properties.Formula:C26H26FN5OColor and Shape:SolidMolecular weight:443.52RET-IN-10
CAS:RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).Formula:C29H28N8OSColor and Shape:SolidMolecular weight:536.65RET-IN-7
CAS:RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice throughFormula:C22H24ClFN6O2Color and Shape:SolidMolecular weight:458.92RET-IN-1
CAS:RET-IN-1 is a RET kinase inhibitor (IC50s: 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively).Formula:C29H31N9O3Purity:98%Color and Shape:SolidMolecular weight:553.61WF-47-JS03
WF-47-JS03: RET kinase inhibitor, crosses blood-brain barrier, 500x more selective for KDR, IC50: 1.7 nM in Ba/F3 cells, 5.3 nM in LC-2/ad lung cancer cells.
Formula:C30H38N6O2Color and Shape:SolidMolecular weight:514.66Enbezotinib
CAS:Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.Formula:C21H21FN6O3Purity:99.84%Color and Shape:SolidMolecular weight:424.43Ref: TM-T62285
1mg77.00€5mg166.00€10mg253.00€25mg414.00€50mg567.00€100mg745.00€1mL*10mM (DMSO)182.00€
